-

iVeena Announces Successful Completion of Pre-IND Meeting with FDA

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, announces successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for a novel pharmacologic treatment of pediatric myopia.

IVMED-85 enables physiologic crosslinking in the sclera and cornea to arrest progression of myopia. The investigational formulation is a once daily topical eye drop. This innovative approach and mechanism of action have previously not been studied clinically. In line with this novel approach the FDA confirmed a 505(b)(1) regulatory submission is appropriate, a drug development pathway for products with no prior regulatory approvals.

Key nonclinical and clinical development milestones were discussed at the meeting. The FDA provided guidance in support of iVeena’s proposed first in human trial, as well as gave clear expectations for endpoints and design of the future pivotal clinical program that will aim to define the product’s safety and efficacy needed for approval. Additionally, clarity was provided regarding the structure and species of the toxicology program.

“We appreciate the guidance from the FDA as we move into the toxicology program and prepare for the clinic in 2022,” said iVeena CEO Jerry Simmons. “This engagement with the FDA is significant progress for IVMED-85 development and gives us confidence in our development plan of this novel therapeutic.”

About IVMED-85

IVMED-85 is an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. Copper ion is a cofactor for lysyl oxidase (LOX) activity, which mediates physiologic collagen crosslinking and is reduced in myopic sclera. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia control.

About Pediatric Myopia

Myopia, also known as nearsightedness, is a vision condition in which people can see close objects clearly, but objects farther away appear blurred. Myopia is considered an epidemic and is projected to inflict half the world population by the year 2050. The incidence of myopia increases throughout the childhood years, typically beginning at about age 5 or 6 and may worsen as the child ages. Nearsightedness poses risks to kids including playground or activity injuries, impaired academic performance, and increased risk of developing glaucoma, cataract, maculopathy, and retinal detachment. Slowing the progression of myopia could enhance quality of life and long-term ocular health.

About iVeena

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing a non-surgical, non-invasive, pharmacologic innovation. This novel disease modifying intervention addresses a significant unmet need in the advancement of corneal diseases and myopic conditions. The company’s lead programs comprise novel proprietary eye drops; IVMED-80, granted Orphan Drug Designation, for keratoconus and IVMED-85 for myopia.

Contacts

iVeena Delivery Systems, Inc.
Michael Burr, MS, MBA
Vice President of Product Development
mburr@iveenamed.com

iVeena

Details
Headquarters: Salt Lake City, Utah
CEO: Robert Dempsey
Employees: 8
Organization: PRI

Release Versions

Contacts

iVeena Delivery Systems, Inc.
Michael Burr, MS, MBA
Vice President of Product Development
mburr@iveenamed.com

More News From iVeena

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million. This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025. “We are pleased to welcome Dr. Jerry Hu to our Board...

iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progres...

Glaukos Licenses Iveena’s Investigational Keratoconus Therapy

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transpl...
Back to Newsroom